Medigene and Azanta enter Agreement for Commercialization of Veregen® in the Nordic Countries
(Thomson Reuters ONE) -
MediGene AG /
Medigene and Azanta enter Agreement for Commercialization of Veregen® in the
Nordic Countries
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Market launch in Denmark, Sweden, Finland and Norway scheduled for early 2013
Martinsried/Munich, June 14, 2012. Medigene AG (Frankfurt, Prime Standard;
XETRA: MDG) and the Danish pharmaceutical company, Azanta A/S, have entered an
exclusive agreement for the supply and marketing of Veregen(®) for the treatment
of genital and perianal warts in Denmark, Sweden, Norway, Finland, and Iceland.
Medigene will benefit from a one-time upfront payment, the supply of the
finished product as well as double-digit royalties on sales of Veregen(®) in
these countries.
Azanta is planning to launch Veregen(®) in Denmark, Sweden, Finland, and Norway
in early 2013. Marketing authorization applications for these and several other
European countries were positively assessed by the respective regulatory
authorities in March 2012. Market approvals for Sweden and Norway have already
been granted, and Medigene anticipates that the other national marketing
authorizations will be formally granted within the next few months. The
marketing authorization applications for Iceland and several other countries are
in preparation.
Dr. Frank Mathias, Chief Executive Officer of Medigene AG, commented: "We are
delighted that Azanta, a fast-growing, specialty pharma company, will
commercialize Veregen(®) in the Nordic countries. With their local expertise, we
should be able to quickly penetrate the Scandinavian pharmaceutical market with
our innovative product, and continue to broaden the distribution of Veregen(®)
throughout Europe".
Dr. Claus Møller, Chief Executive Officer of Azanta A/S, commented: "Veregen(®)
supplements Azanta's existing women's and men's healthcare portfolio, and the
product is optimally suited for our company's specialty pharma marketing and
growth strategy. Veregen(®) will play a key role in our company, and will
contribute to a further enhancement of our positioning in the Nordic region".
Veregen(®) is already being marketed successfully in the USA (by Fougera),
Germany and Austria (by Abbott), and Spain (by Bial). Marketing authorizations
in additional countries are granted or expected within the next few months.
Medigene has entered into several marketing partnerships for Veregen across
Europe, Asia, and America and is planning to continue this global licensing
strategy.
About Veregen(®): Veregen(®) (previously Polyphenon E(®) ointment), a topical
treatment for external genital or perianal warts, contains a concentrate of
catechins with a complex defined composition extracted from green tea leaves.
Medigene acquired the rights to the active ingredient in Veregen(®) from Epitome
Pharmaceuticals, Inc. in 1999 and was solely responsible for the drug's
successful preclinical and clinical development, as well as the regulatory
approval process. Sinecatechins 15% ointment (Veregen(®)) is recommended as an
option for treating genital warts in the US Department of Health and Human
Services Center for Disease Control and Prevention's Sexually Transmitted
Diseases Treatment Guidelines 2010.
Azanta A/S is a privately owned specialty pharma company primarily operating
within oncology, women's and men's health and addiction medicine. The vision of
Azanta A/S is to become an international market leader within specialty pharma
products and innovative pharmaceutical products. Azanta A/S currently markets or
makes available nine specialty pharma products, including Nimoral, a hypoxic
radio sensitizer for the treatment of head and neck cancer patients undergoing
primary radiotherapy. In addition, Azanta A/S has a portfolio of low risk
development projects for commercialization within a shorter time period.
For further information, please visit www.azanta.com.
Medigene AG is a publicly listed (Frankfurt: MDG, prime standard) biotechnology
company headquartered in Martinsried/Munich, Germany. Medigene focuses on
clinical research and development of novel drugs against cancer and autoimmune
diseases. Medigene is the first German biotech company to have revenues from
marketed products, which are distributed by partner companies. It has two drug
candidates in clinical trials and is developing an innovative vaccine
technology.
For more information, please visit www.medigene.com.
This press release contains forward-looking statements representing the opinion
of Medigene as of the date of this release. The actual results achieved by
Medigene may differ significantly from the forward-looking statements made
herein. Medigene is not bound to update any of these forward-looking statements.
Medigene(®) and Veregen(®) are registered trademarks of Medigene AG. Polyphenon
E(® )is a trademark of Mitsui Norin Co., Ltd. These trademarks may be owned or
licensed in select locations only.
- End -
Contact Medigene
Julia Hofmann & Kerstin Langlotz
Tel.: +49 - 89 - 20 00 33 - 33 01
Fax: +49 - 89 - 20 00 33 - 29 20
Email: investor(at)medigene.com
Contact Azanta
Claus Møller
Tel: + 45 - 70 25 95 45
Fax: + 45 - 70 25 95 46
Email: info(at)azanta.com
To unsubscribe from the press release distribution list, please go to
www.medigene.com/unsubscribe.
Press release as pdf:
http://hugin.info/132073/R/1619502/517266.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MediGene AG via Thomson Reuters ONE
[HUG#1619502]
Unternehmensinformation / Kurzprofil:
Datum: 14.06.2012 - 08:30 Uhr
Sprache: Deutsch
News-ID 156419
Anzahl Zeichen: 6836
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 202 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Medigene and Azanta enter Agreement for Commercialization of Veregen® in the Nordic Countries"
steht unter der journalistisch-redaktionellen Verantwortung von
MediGene AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
